Clinical Trial Update: A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease [Phase 2]

View source ↗

Summary

A Phase 2, 18-month study evaluating the efficacy, safety, tolerability, and pharmacokinetics of oral UCB0599 in early-stage Parkinson's disease has been comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• UCB0599

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Early-stage Parkinson's Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-10-31